Atopic dermatitis in children, part 2: Treatment options

Cutis

Volumn 78, Issue 6, 2006, Pages 401-406

  Kiken, David A ^a   Silverberg, Nanette B ^{a,b,c,d,e,f,g}  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f Hill Dermaceuticals Inc   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CALCINEURIN;

ATOPIC DERMATITIS; CHILD; DRUG ANTAGONISM; HUMAN; PHOTOTHERAPY; PRESCHOOL CHILD; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; HUMANS; PHOTOTHERAPY;

EID: 33846174278     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Kiken DA, Silverberg NB. Atopic dermatitis in children, part 1: epidemiology, clinical features, and complications. Cutis. 2006;78:241-247.
2. Nassif A, Chan SC, Storrs FJ, et al. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol. 1994;130:1402-1407.
3. Breneman DL, Hanifin JM, Berge CA, et al. The effect of antibacterial soap with 1.5% triclocarban on Staphyloccus aureus in patients with atopic dermatitis. Cutis. 2000;66:296-300.
4. Ricci G, Patrizi A, Bellini F, et al. Use of textiles in atopic dermatitis: care of atopic dermatitis. Curr Probl Dermatol. 2006;33:127-143.
5. Bendsoe N, Bjornberg A, Asnes H. Itching from wool fibers in atopic dermatitis. Contact Dermatitis. 1987;17:21-22.
6. Loden M. Biophysical properties of dry atopic and normal skin with special reference to effects of skin care products. Acta Derm Venereol Suppl (Stockh). 1995;192:1-48.
7. Carr JD. Emollient treatment for childhood eczema: involving children and parents. J Fam Health Care. 2006;16:105-107.
8. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324.
9. Lucky AW. Principles of the use of glucocorticosteroids in the growing child. Pediatr Dermatol. 1984;1:226-235.
10. Gallant C, Kenny P. Oral glucocorticoids and their complications. a review. J Am Acad Dermatol. 1986;14:161-177.
11. Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol. 2000;106:651-659.
12. Barnes PJ. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol. 2000;106:5-16.
13. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992;27:29-34.
14. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994;131:536-540.
15. Elocon. In: Physicians' Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005.
16. Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2001;44(suppl 1):S17-S27.
17. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102(4 pt 1):637-644.
18. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(suppl 1):S47-S57.
19. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997;137:568-576.
20. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003;111:1153-1168.
21. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143:718-726.
22. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001;20:233-241.
23. Berth-Jones AA, Bos JD, Giannetti A, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004;151:3-27.
24. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(suppl 1):S28-S38.
25. Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(suppl 1):S39-S46.
26. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis: The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999-1006.
27. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(suppl 1):S58-S64.
28. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-562.
29. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dematol. 2004;51:515-525.
30. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110:277-284.
31. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142:155-162.
32. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
33. Wahn U, Bos JD, Goodfield M, et al; Flare Reduction in Eczema With Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 pt 1):e2.
34. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271-277.
35. Silverberg NB. The new therapeutic dilemma in pediatrics [editorial]. Cutis. 2005;75:205-206.
36. US Food and Drug Administration. FDA Talk Paper: FDA Issues Public Health Advisory Informing Health Care Providers of Safety Concerns Associated With the Use of Two Eczema Drugs, Elidel and Protopic. Rockville, Md: FDA Office of Public Affairs; March 10, 2005. Talk Paper T05-06.
37. Hill B. Topical immunosuppressants (calcineurin inhibitors) - animal toxicology. Available at: www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4089s2_01_06_Hill.ppt. Accessed March 20, 2005.
38. La Rosa M, Ranno C, Musarra I, et al. Double blind study of citirazine in atopic eczema in children. Ann Allergy. 1994;73:117-122.
39. Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology. 2002;205:40-45.
40. Dimson S, Nanayakkara C. Do oral antihistamines stop the itch of atopic dermatitis? Arch Dis Child. 2003;88:832-833.
41. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160.
42. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23:123-127.
43. Udo EE, Pearman JW, Grubb WB. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect. 1994;26:157-165.
44. Jekler J, Larkö O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol. 1991;125:569-572.
45. George SA, Bilsland DJ, Johnson BE, et al. Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol. 1993;128:49-56.
46. Grundmann-Kollmann M, Behrens S, Podda M, et al. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol. 1999;40:995-997.
47. Sheehan MP, Atherton DJ, Norris P, et al. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol. 1993;129:431-436.
48. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet. 2001;357:2012-2016.
49. Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45:503-507.
50. Tsitoura S, Nestoridou K, Botis P, et al. Randomized trial to prevent sensitization to mite allergens in toddlers and preschoolers by allergen reduction and education: one-year results. Arch Pediatr Adolesc Med. 2002;156:1021-1027.
51. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34:1016-1021.
52. Zonneveld IM, De Rie MA, Beljaards RC, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol. 1996;135:15-20.
53. Stevens SR, Hanifin JM, Hamilton T, et al. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol. 1998;134:799-804.
54. Brehler R, Hildebrand A, Luger TA. Recent developments in the treatment of atopic eczema. J Am Acad Dermatol. 1997;36:983-994.
55. Xu X-J, Banerjee P, Rustin MHA, et al. Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema. Br J Dermatol. 1997;136:54-59.
56. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet. 1992;340:673-674.